Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News on Pharma

The hospital ran out of her child's cancer drug. Now she's fighting to end shortages

Laura Bray couldn't watch her 9-year-old's leukemia go untreated. She started campaigning to fix a broken system and get patients the treatments they need in the face of drug shortages.

WEKU

Law enforcement eyes opioid settlement cash for squad cars and body scanners

Some state and local governments have started tapping in to opioid settlement funds for law enforcement expenses. Many argue it should go toward treating addiction instead.

WEKU

3 Revolutionary Biotech Stocks Worth Investing In

The biotech industry's upward momentum is underpinned by the growth of personalized medicine, orphan drugs, innovative biotech tools, and robust government backing. Hence, revolutionary biotech stocks Equillium (EQ), Protalix BioTherapeutics (PLX), and Incyte Corporation (INCY) could make ideal additions to your portfolio at present. Read more….

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

Medsafe overrides its Medicines Classification Committee on cannabis

The committee advised against over-the-counter CBD sales late last year

Newsroom.co.nz

3 Promising Pharma Stocks to Keep on Your Radar

The pharma industry’s prospects look bright, thanks to rising demand for generic and innovative drugs and technological advancements. Hence, adding fundamentally strong pharma stocks Astellas Pharma (ALPMY), Sanofi (SNY), and GSK (GSK) to one’s watchlist could be wise. Keep reading.

StockNews.com

3 Biotech Stocks for Long-Term Value

With medical innovations and a rising geriatric population, biotech stocks have garnered significant attention. Thus, sound biotech stocks like Genfit (GNFT), Entrada Therapeutics (TRDA), and MacroGenics (MGNX) could prove to be valuable portfolio additions in the long term. Read on….

StockNews.com

Abbott Laboratories (ABT) Earnings Insights: Will the Medical Stock Build Investor Confidence?

Considering Abbott Laboratories' (ABT) recent strategic collaborations and acquisitions to boost the company’s long-term growth, could the stock be a compelling buy as we approach its fiscal third-quarter earnings release? Let's find out.

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

Pfizer cuts full-year outlook due to declining sales of Covid-19-related products

Shares of Pfizer are falling before the opening bell as the company cut its full-year outlook, citing declining sales of its COVID-19-related products

The Independent UK

How to Enhance Your Own Strategies with POWR Ratings

Wall Street is never lacking in strategy or trading ideas. In investing, if you can combine two or more strategies that align around a particular investing idea, you can enhance your likelihood of success. This idea combines our POWR Ratings with a strategy that is currently making the rounds on…

StockNews.com

Johnson & Johnson (JNJ) vs. Madrigal Pharmaceuticals (MDGL): Which Pharma Stock Is a Worthier October Investment?

With an aging population worldwide, the growing prevalence of chronic diseases, new drug discoveries and rapid digital advancements, the outlook for the pharmaceutical sector remains optimistic. Pharma stocks Johnson & Johnson (JNJ) and Madrigal Pharmaceuticals (MDGL) will likely benefit from the industry’s bright prospects. But which of these stocks is…

StockNews.com

EU orders biotech giant Illumina to unwind $7.1 billion purchase of cancer-screening company Grail

The European Union is ordering U.S. biotech giant Illumina to undo its $7.1 billion purchase of cancer-screening company Grail because it closed the deal without approval of regulators

The Independent UK

Politicians come and go, but the clock is now ticking on long-promised pharmacare

The sword of Damocles hangs over the Trudeau government as it prepares a pharmacare bill that must be passed this year to uphold its supply and confidence agreement with the NDP. This month might be the most crucial time in the history of pharmacare, the long-promised yet undelivered program that…

The Conversation

India allows cough syrup firm linked to Uzbek deaths to re-open factory, shows document

Uttar Pradesh has permitted the resumption of most production at a factory owned by Marion Biotech, which produced cough syrups Uzbekistan linked to the deaths of 65 children last year, an order seen by Reuters shows.

The Hindu

CSL to bandage cost pressures to stem bleeding profits

Biomedical giant CSL has pledged to repair margins as cost pressures and volatile global currencies continue to bruise profits at the vaccine and plasma leader.

AAP

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Michigan State instructor discovered to have meth lab conviction

Brendan Doyle, a kinesiology instructor, had been reportedly exhibiting erratic behaviour

StockNews.com

3 Pharma Stocks Ready to Shine This Week

The pharmaceutical industry is expected to thrive, driven by the increasing need for chronic disease management and the requirements of an aging demographic. Given the industry’s solid prospects, quality pharma stocks Organon (OGN), GoodRx Holdings (GDRX), and Collegium Pharmaceutical (COLL) could be solid buys this week. Read on….

StockNews.com

Earnings Watch: Is Walgreens Boots Alliance (WBA) a Solid Buy Before Earnings?

Retail drugstore chain Walgreens Boots Alliance (WBA) achieved adjusted EPS growth on solid sales increase in the third quarter of fiscal 2023. However, the company lowered its full-year earnings guidance to reflect challenging consumer and macro conditions and lower COVID-19 demand. So, let’s determine if WBA is a buy before…

The Independent UK

Georgia will be first state with medical marijuana in pharmacies

Georgia soon will become the first state in the nation to offer medical marijuana products at independent pharmacies

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

3 Pharma Stocks With Potential to Outperform Pfizer Inc. (PFE) in October

Pfizer (PFE) is grappling with financial difficulties and declining performance. Yet, with growing pharmaceutical demand and industry advancements, robust pharma stocks Zoetis (ZTS), Horizon Therapeutics (HZNP), and Novartis (NVS) appear as more promising buys this month. Read on.

StockNews.com

Which Pharma Stock Has More Potential Gains This Month: Pfizer (PFE) or Eli Lilly & Co. (LLY)?

The pharmaceutical industry is poised for sustained long-term growth due to increased investments in drug development and rapid technological advancements. While leading pharma stocks Pfizer (PFE) and Eli Lilly (LLY) stand to benefit, let us analyze which of these giants is poised for more gains this month. Keep reading.

StockNews.com

Top 3 Biotech Stocks Leading the Way This October

The biotech industry is well-positioned for strong growth thanks to increasing demand for high-quality treatments for chronic diseases. Given this backdrop, quality biotech stocks Jazz Pharmaceuticals (JAZZ), Amgen (AMGN), and Gilead Sciences (GILD) could be solid buys for October. Read on….

The Hindu

Letters to The Editor — October 3, 2023

Readers’ mail to The Hindu’s Letters to The Editor

The Hindu

Johnson & Johnson not to enforce patents on TB drug

“The announcement will finally pave the way for unfettered access to affordable generic versions of bedaquiline for all people”

WEKU

Have a complaint about CVS? So do pharmacists: Many just walked out

After a large walkout forced at least a dozen stores to shut down in the Kansas City area, CVS promises change. But critics say the crisis in staffing and unfair pay extends beyond that market.

The Independent UK

Vivek Ramaswamy is furiously defending his business ties in China. What are they?

‘Vivek’s first business had a subsidiary in China’ which was closed ‘as the risks of doing business in China became apparent,’ Ramaswamy spokesperson says

1 … 43 44 45 46

People

Mangeet Kaur BounsMangeet

Sristi Suman JayaswalThe

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.